Login to Your Account



Other News To Note


Thursday, January 26, 2012
• Neurocrine Biosciences Inc., of San Diego, said its VMAT2 inhibitor candidate, NBI-98854, was granted fast-track designation by the FDA in neuroleptic-induced tardive dyskinesia. NBI-98854 is designed to modulate dopamine release during nerve communication with minimal impact on the other monoamines, reducing the likelihood of off-target side effects. The compound may be effective in disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome and tardive dystonia. Last week, the company priced a public offering, seeking to raise $77 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription